These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25260843)

  • 21. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review.
    Calvo-Río V; de la Hera D; Beltrán-Catalán E; Blanco R; Hernandez M; Martínez-Costa L; Loricera J; Cañal J; Ventosa J; Ortiz-Sanjuán F; Pina T; González-Vela MC; Rodríguez-Cundín P; González-Gay MA
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S54-7. PubMed ID: 25005576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition.
    Camellino D; Soldano S; Cutolo M; Cimmino MA
    Rheumatol Int; 2018 Sep; 38(9):1699-1704. PubMed ID: 29946742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refractory neuro-Behçet treated by tocilizumab: a case report.
    Urbaniak P; Hasler P; Kretzschmar S
    Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S73-5. PubMed ID: 23020826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AA amyloidosis treated with tocilizumab: case series and updated literature review.
    Courties A; Grateau G; Philippe P; Flipo RM; Astudillo L; Aubry-Rozier B; Fabreguet I; Fahd W; Fain O; Guggenbuhl P; Hachulla E; Papo T; Richez C; Sibilia J; Morel J; Berenbaum F; Sellam J;
    Amyloid; 2015; 22(2):84-92. PubMed ID: 25585627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new alternative therapy in dermatology: tocilizumab.
    Koryürek ÖM; Kalkan G
    Cutan Ocul Toxicol; 2016; 35(2):145-52. PubMed ID: 26023856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
    Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
    Mod Rheumatol; 2014 Jan; 24(1):17-25. PubMed ID: 24261754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tocilizumab in adult-onset Still's disease: the Israeli experience.
    Elkayam O; Jiries N; Dranitzki Z; Kivity S; Lidar M; Levy O; Ablin J; Abu-Shakra M; Savargyl-Maman H; Padova H; Caspi D; Rosner I
    J Rheumatol; 2014 Feb; 41(2):244-7. PubMed ID: 24429168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.
    Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
    Mod Rheumatol; 2014 Jan; 24(1):26-32. PubMed ID: 24261755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet's syndrome: case series and literature review.
    Liu J; Yan D; Wang Z; Yang Y; Zhang S; Wu D; Peng L; Liu Z; Zheng W
    Ther Adv Musculoskelet Dis; 2020; 12():1759720X20971908. PubMed ID: 33240406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tocilizumab: a novel therapy for patients with large-vessel vasculitis.
    Salvarani C; Magnani L; Catanoso M; Pipitone N; Versari A; Dardani L; Pulsatelli L; Meliconi R; Boiardi L
    Rheumatology (Oxford); 2012 Jan; 51(1):151-6. PubMed ID: 22075063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tocilizumab and refractory Takayasu disease: Four case reports and systematic review.
    Decker P; Olivier P; Risse J; Zuily S; Wahl D
    Autoimmun Rev; 2018 Apr; 17(4):353-360. PubMed ID: 29427826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
    Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
    J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab in refractory adult Still's disease.
    Puéchal X; DeBandt M; Berthelot JM; Breban M; Dubost JJ; Fain O; Kahn JE; Lequen L; Longy-Boursier M; Perdriger A; Schaeverbeke T; Toussirot E; Sibilia J;
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):155-9. PubMed ID: 20740616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Brain MRI of reversible, recurrent white matter lesions in a patient with a 35-year history of neuro-Behçet disease].
    Fukuda K; Ishida S; Sakane S; Furukawa K; Sugino M
    Brain Nerve; 2009 Jun; 61(6):701-5. PubMed ID: 19526839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.
    Nakashima Y; Kondo M; Harada H; Horiuchi T; Ishinishi T; Jojima H; Kuroda K; Miyahara H; Nagamine R; Nakashima H; Otsuka T; Saikawa I; Shono E; Suematsu E; Tsuru T; Wada K; Iwamoto Y
    Mod Rheumatol; 2010 Aug; 20(4):343-52. PubMed ID: 20480201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease.
    Redondo-Pachón MD; Enríquez R; Sirvent AE; Andrada E; Noguera-Pons R; Millán I; Amorós F
    Ren Fail; 2013; 35(4):547-50. PubMed ID: 23472940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tocilizumab, an effective treatment for relapsing giant cell arteritis.
    Oliveira F; Butendieck RR; Ginsburg WW; Parikh K; Abril A
    Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S76-8. PubMed ID: 24854376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study.
    Nishina N; Kaneko Y; Kameda H; Takeuchi T
    Mod Rheumatol; 2015 May; 25(3):401-4. PubMed ID: 25401229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes.
    Atienza-Mateo B; Beltrán E; Hernández-Garfella M; Valls Pascual E; Martínez-Costa L; Atanes A; Moriano C; Cordero-Coma M; Nolla JM; Carrasco Cubero C; Sánchez Martín J; Calvo-Río V; Demetrio R; Palmou-Fontana N; González-Gay MÁ; Blanco R
    Clin Exp Rheumatol; 2021; 39 Suppl 132(5):37-42. PubMed ID: 33886457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
    Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schulze-Koops H; Schett G; Spiera R; Unizony SH; Collinson N
    Arthritis Rheumatol; 2019 Aug; 71(8):1329-1338. PubMed ID: 30835950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.